.png){kind=icon}
.png){kind=icon}
Return
HER-2 directed therapies across gastrointestinal tract cancers - A new frontier
.png){kind=icon}
OA
AI
DOI：10.1016/j.ctrv.2024.102789.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Gastrointestinal (GI) cancers are common and in the metastatic setting they have a poor prognosis. The current mainstay of treatment of GI cancers is chemotherapy; however, the biomarker-directed treatment landscape is evolving. HER-2 is overexpressed in a portion of GI cancers and is an emerging target for therapy, with recent FDA tumor agnostic approval for trastuzumab deruxtecan. Testing for HER-2 expression is not standardized across GI cancers, methodology requires further optimization and standardization as HER-2 targeted therapy emerges into the treatment landscape. There is established rationale for use of HER-2 targeted therapy in first line treatment of metastatic gastric cancer, and emerging evidence with variable benefit in bile duct, pancreatic and colorectal cancers.
Keywords:
HER-2
Gastrointestinal cancer
Gastric cancer
Biliary cancer
Pancreatic cancer
Colorectal cancer
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
